Страна: Великобритания
Язык: английский
Источник: MHRA (Medicines & Healthcare Products Regulatory Agency)
Mirtazapine
Phoenix Healthcare Distribution Ltd
N06AX11
Mirtazapine
30mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 04030400
1.3.1 SPC, LABELLING AND PACKAGE LEAFLET PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON 1. NAME OF THE MEDICINAL PRODUCT Mirtazapine 15 mg orodispersible tablets Mirtazapine Mirtazapine 30 mg orodispersible tablets Mirtazapine Mirtazapine 45 mg orodispersible tablets Mirtazapine 2. STATEMENT OF ACTIVE SUBSTANCE(S) Each orodispersible tablet contains 15 mg mirtazapine. Each orodispersible tablet contains 30 mg mirtazapine. Each orodispersible tablet contains 45 mg mirtazapine. 3. LIST OF EXCIPIENTS Contains aspartame (E951), see leaflet for further information. 4. PHARMACEUTICAL FORM AND CONTENTS Orodispersible tablet _6 orodispersible tablets _ _18 orodispersible tablets _ _30 orodispersible tablets _ _48 orodispersible tablets _ _90 orodispersible tablets _ _96 orodispersible tablets _ 5. METHOD AND ROUTE(S) OF ADMINISTRATION _ _ Oral use. Read the package leaflet before use. 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN Keep out of the sight and reach of children. 1.3.1 SPC, LABELLING AND PACKAGE LEAFLET 7. OTHER SPECIAL WARNING(S), IF NECESSARY ------- 8. EXPIRY DATE EXP _ _ 9. SPECIAL STORAGE CONDITIONS ------- 10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE ------- 11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER Bluefish Pharmceuticals AB, Stockholm, Sweden. 12. MARKETING AUTHORISATION NUMBER(S) Mirtazapine 15 mg Orodispersible Tablets: PL 31774/0013 Mirtazapine 30 mg Orodispersible Tablets: PL 31774/0014 Mirtazapine 45 mg Orodispersible Tablets: PL 31774/0015 13. BATCH NUMBER Lot 14. GENERAL CLASSIFICATION FOR SUPPLY 15. INSTRUCTIONS ON USE ------- 16. INFORMATION IN BRAILLE Mirtazapine 15 mg Mirtazapine 30 mg Mirtazapine 45 mg POM 1.3.1 SPC, LABELLING AND PACKAGE LEAFLET 17. UNIQUE IDENTIFIER – 2D BARCODE_ _ <2D barcode carrying the unique identifier included.> 18. UNIQUE IDENTIFIER - HUMAN READABLE DATA_ _ PC: {number} SN: {number} NN: {number} 1 Прочитать полный документ
1. NAME OF THE MEDICINAL PRODUCT Mirtazapine 30mg tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 30 mg of mirtazapine. Excipient with known effects: Lactose monohydrate: 203.60 mg For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Film-coated tablet. Brownish, scored on both sides, 12.7 x 6.5 mm oval, biconvex, film-coated tablets. Marked with I on one side. 4. CLINICAL PARTICULARS 4.1. THERAPEUTIC INDICATIONS Major depressive episode. 4.2. POSOLOGY AND METHOD OF ADMINISTRATION Adults The effective daily dose is usually between 15 and 45 mg; the starting dose is 15 or 30 mg. Mirtazapine begins to exert its effect in general after 1-2 weeks of treatment. Treatment with an adequate dose should result in a positive response within 2-4 weeks. With an insufficient response, the dose can be increased up to the maximum dose. If there is no response within a further 2-4 weeks, then treatment should be stopped. Elderly The recommended dose is the same as that for adults. In elderly patients an increase in dosing should be done under close supervision to elicit a satisfactory and safe response. Children and adolescents under the age of 18 years Mirtazapine should not be used in children and adolescents under the age of 18 years as efficacy was not demonstrated in two short-term clinical trials (see section 5.1) and because of safety concerns (see sections 4.4, 4.8 and 5.1). Renal impairment The clearance of mirtazapine may be decreased in patients with moderate to severe renal impairment (creatinine clearance < 40 ml/min ). This should be taken into account when prescribing mirtazapine to this category of patients (see section 4.4). Hepatic impairment The clearance of mirtazapine may be decreased in patients with hepatic impairment. This should be taken into account when prescribing mirtazapine to this category of patients, particularly with severe hepatic impairment, as patients with severe hepatic impairment have not been investigated (see section 4.4). Mirtazapin Прочитать полный документ